Liver Cancer and Risk Factors in the MENA Region: Epidemiology and Temporal Trends Based on the 2019 Global Burden of Disease Data DOI Creative Commons
Najla A. Lakkis,

Nour M. Mokalled,

Mona H. Osman

et al.

Cancer Control, Journal Year: 2024, Volume and Issue: 31

Published: Jan. 1, 2024

Liver cancer (LivCa) is a growing concern in the MENA region, driven by diverse factors, including viral hepatitis, lifestyle-related risks, and other causes.

Language: Английский

The latest global burden of liver cancer: A past and present threat DOI Creative Commons
Joo Hyun Oh, Dae Won Jun

Clinical and Molecular Hepatology, Journal Year: 2023, Volume and Issue: 29(2), P. 355 - 357

Published: March 9, 2023

Language: Английский

Citations

78

Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients DOI
Maria Eva Argenziano, Mi Na Kim, Michele Montori

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(S2), P. 922 - 940

Published: July 16, 2024

Language: Английский

Citations

13

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment DOI Creative Commons
Soo Young Hwang, Pojsakorn Danpanichkul, Vatche G. Agopian

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 26, 2024

Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality.HCC due to chronic hepatitis B virus (HBV) or C (HCV) infection has decreased universal vaccination for HBV and effective antiviral therapy both HCV, but HCC related metabolic dysfunction associated steatotic liver disease (MASLD) alcohol-associated (ALD) increasing.Biannual ultrasonography serum α-fetoprotein are primary surveillance tools early detection among high-risk patients (e.g., cirrhosis, HBV).Alternative such blood-based biomarker panels abbreviated MRIs being investigated.Multiphasic CT MRI standard diagnosis, histological confirmation should be considered, especially when inconclusive findings seen on cross-sectional imaging.Staging treatment decisions complex made in multidisciplinary settings, incorporating multiple factors including tumor degree dysfunction, patient performance status, available expertise, preferences.Early-stage best treated with curative options resection, ablation, transplantation.For intermediatestage disease, locoregional therapies primarily recommended although systemic may preferred large intrahepatic burden.In advanced-stage immune checkpoint inhibitor (ICI)-based regimen.In this review article, we discuss recent epidemiology, risk factors, care continuum encompassing surveillance, staging, treatments.

Language: Английский

Citations

11

Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021 DOI Creative Commons
Si Yang,

Yujiao Deng,

Yi Zheng

et al.

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 11, 2025

Liver cancer (LC) is a major concern in the Asia-Pacific region, particularly China, Korea, and Japan. In this study, we aimed to investigate burden, trends, predictions related LC these countries. Using data from Global Burden of Disease Study 2021, epidemiological characteristics [incidence, deaths, disability-adjusted life-years (DALYs)] for were analysed stratified by specific etiologies Japan, South Korea. We examined temporal trends burden over last 32 years projected changes following 25 years. The risk factors associated with deaths DALYs also investigated. highest LC-related incidence, mortality, recorded China (196,637 incidents, 172,068 mortalities, 4,890,023 DALYs), lowest Korea (18,642 13,674 326,336 DALYs). age-standardized rates (ASRs) (19.94 per 100,000, 14.53 354.57 100,000), Japan (9.89, 7.29, 145.74, respectively). From 1990 incidents three countries increased, ASRs decreased. caused five increased past years, non-alcoholic steatohepatitis (NASH) was largest increasing China. Infections hepatitis B virus remained leading cause while C prevailing High body mass index (BMI) most sharply factor Alcohol drug use main respectively. rise steadily between 2022 2046. remains significant disease now next Regarding factors, NASH high BMI alcohol should receive attention.

Language: Английский

Citations

2

Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990–2019: a decomposition and age–period–cohort analysis DOI
Chunlong Liu, Shijie Zhu, Jian Zhang

et al.

Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 58(12), P. 1222 - 1236

Published: Sept. 4, 2023

Language: Английский

Citations

19

Epidemiological trends in gastrointestinal cancers and risk factors across U.S. states from 2000 to 2021: a systematic analysis for the global burden of disease study 2021 DOI Creative Commons
Jiahao Jiang, Zhiqin Xie, Qingbin Wang

et al.

BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 6, 2025

Gastrointestinal (GI) cancers account for over a quarter of all cancer-related deaths in the United States; however, latest trends their prevalence remain unclear. Data on GI were obtained from Global Burden Disease Study 2021. Age-standardized incidence rates (ASIR) and age-standardized mortality (ASMR) estimated across various states, sexes, ages, risk factors, annual percentage changes calculated. From 2000 to 2021, liver cancer exhibited greatest increase both ASIR ASMR, followed by pancreatic cancer. In contrast, stomach showed decline, colorectal cancer, esophageal biliary tract Most predominantly affect men tend toward younger age onset. Geographic disparities exist burden factors. For esophageal, stomach, cancers, linked diet smoking decreased, whereas alcohol-related increased several especially West Virginia. Hepatitis C remains leading cause with intravenous drug use as primary factor. Non-alcoholic steatohepatitis (NASH) is fastest-growing excessive alcohol use. Mortality due high body-mass index fasting plasma glucose have states groups. The epidemiological U.S. shifted substantially. States need implement targeted policies that address specific populations factors each type.

Language: Английский

Citations

1

Systems pharmacology of phytochemical anacardic acid in the chemoprevention of hepatocellular carcinoma DOI

Sangita Panda,

Enketeswara Subudhi, Sweta Padma Routray

et al.

Drug Metabolism and Personalized Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 22, 2025

Abstract Objectives Hepatocellular carcinoma (HCC) is a common type of liver cancer that progresses quickly and has limited treatment options. Nutraceutical anacardic acid (AA), bioactive compound derived from cashew nut shell, emerged as potential candidate for HCC owing to its reported anti-inflammatory, anticancer diverse pharmacological properties. In the present study, we investigate AA an inhibitor using molecular docking, gene ontology, network pharmacology. Methods The pharmacokinetic physicochemical properties were assessed Swiss ADME. SuperPred, Similarity Ensemble Approach, ChEMBL Target Prediction online tools used determining targets AA. addition, GeneCards, NCBI, DisGeNET UniProt ID search top 25 hub genes determined Cytohubba plugin. A protein interaction (PPI) was constructed through STRING database. Gene Ontology (GO) biological process Kyoto Encyclopaedia Genes (KEGG) pathway enrichment analysis performed FunRich ShinyGO 0.77. Moreover, docking studies on NF-κB GSK-3β. expression levels also validated by western blotting. Results Comprehensive data identified 375 11,333 HCC, with 264 in common. Network key targets, including caspase-3, NF-κB. ontology topology highlighted essential pathways implicated progression such renin-angiotensin system, VEGF signalling, apoptosis. Molecular revealed strong binding affinity proteins Upregulation p-NRF2 p-GSK-3β, downregulation p-NF-κB caspase-1 Conclusions Taken together, our study highlights promising chemopreventive agent because significant modulatory effects important regulatory linked cell division, inflammation, apoptosis, antioxidant response.

Language: Английский

Citations

1

Impact of drug dispersion on tumor-effector dynamics during combined chemo-immunotherapy with sensitivity analysis DOI
Lazaro Revocatus Mashiku, J. P. Ndenda, Reuben S. Maghembe

et al.

Applied Mathematical Modelling, Journal Year: 2024, Volume and Issue: 134, P. 148 - 174

Published: June 10, 2024

Language: Английский

Citations

6

Global epidemiology of liver cancer 2022: An emphasis on geographic disparities DOI Creative Commons
Qianru Li, Chao Ding,

Maomao Cao

et al.

Chinese Medical Journal, Journal Year: 2024, Volume and Issue: 137(19), P. 2334 - 2342

Published: Sept. 3, 2024

Abstract Background: Liver cancer remains the sixth most commonly diagnosed and third leading cause of cancer-related deaths worldwide, causing a heavy burden globally. An updated assessment global epidemiology liver that addresses geographical disparities is necessary to better understand promote healthcare delivery. Methods: Data were extracted from GLOBOCAN 2022 database, including number, crude, age-standardized rates incidence mortality at global, country, continent, human development index (HDI) regional levels. Age-standardized (incidence mortality) per 100,000 person-years adjusted based on Segi-Doll World standard population. The mortality-to-incidence ratios (MIR) for each region country calculated. HDI gross national income (GNI) obtained, Pearson correlation analysis was conducted with incidence, mortality, MIR. Results: In 2022, approximately 866,136 new cases 758,725 related recorded MIR 0.86. Males had disproportionately higher than females across all levels, highest observed in elderly Geographically, regions included Micronesia, Eastern Asia, Northern Africa, Southeastern Micronesia. Notably, Mongolia strikingly high compared other countries. North America lowest Africa. Negative associations GNI identified, irrespective sex. Conclusions: current underscores presence remarkable geographic heterogeneity, which particularly evident countries varying highlighting urgent need prioritize health accessibility availability achieve inequities.

Language: Английский

Citations

6

Current epidemiology of chronic liver disease DOI Creative Commons
Richie Manikat, Aijaz Ahmed, Donghee Kim

et al.

Gastroenterology report, Journal Year: 2023, Volume and Issue: 12

Published: Dec. 22, 2023

Abstract Chronic liver disease presents a significant global health burden, characterized by several etiologies, including metabolic dysfunction-associated steatotic (MASLD), alcohol-related (ALD), chronic hepatitis B virus infection, and C infection. This review explored current epidemiological trends projections for each etiology, looking into their respective burdens challenges. MASLD, formerly known as nonalcoholic fatty disease, is the most prevalent cause of its incidence prevalence are steadily rising. ALD, fueled increased alcohol consumption, also on rise, with concerning implications future mortality rates. infections remain major public concerns, particularly in specific regions world, necessitating concerted efforts screening treatment. The coronavirus 2019 (COVID-19) pandemic has impacted epidemiology exacerbating rates disrupting healthcare services. Mental issues arising from further complicate treatment making comprehensive strategies essential. Despite advancements treatment, continues to impose substantial economic emphasizing importance preventive measures early intervention. In conclusion, ongoing surveillance research crucial understanding addressing evolving landscape disease. Comprehensive that encompass prevention, screening, different etiologies essential mitigating impact improving patient outcomes.

Language: Английский

Citations

13